AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease – Marketwatch

Avoid use with strong CYP3A inhibitors and potent CYP3A inducers. Avoid simvastatin and lovastatin doses >40 mg — Monitor digoxin levels with initiation of, or any change in, BRILINTA therapy — The most commonly observed adverse reactions …